SSA
DOVA

Schonfeld Strategic Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-51,781
Closed -$1.55M – 1122
2018
Q2 		$1.55M Sell
51,781
-83,219
-62% -$2.27M 0.08% 316
2018
Q1 		$3.66M Buy
+135,000
New +$4.04M 0.27% 104

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Schonfeld Strategic Advisors's DOVA Position: Q3 2018 in Review

Schonfeld Strategic Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2018, closing a stake of 51,781 shares — an estimated $1.55M sold.

Schonfeld Strategic Advisors first reported a position in DOVA in Q1 2018 and held it in 2 quarters. The position peaked at $3.66M in Q1 2018. 63 funds tracked by Wall St. Rank hold DOVA as of Q3 2018.

  • Schonfeld Strategic Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 51,781 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $1.55M.
  • Schonfeld Strategic Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $3.66M in Q1 2018.
  • 63 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.